A phase 2, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of tx000045 after 24 weeks of treatment in patients with pulmonary hypertension secondary to heart failure with preserved ejection fraction (PH-HFpEF)

• Protocol code: TX000045-003
• EudraCT code: _
• Research group: Cardiovascular Diseases
• Service: Cardiology
• Principal investigator:  Rodenas Alesina, Eduard
• Pathology: Malalties del sistema circulatori
• Phase: Fase II